Research programme: antibody therapeutics - Xencor

Drug Profile

Research programme: antibody therapeutics - Xencor

Alternative Names: PD1 x costim bispecific antibodies - Xencor; PD1 x costimulation bispecific antibodies - Xencor; XmAb 14484; XmAb 18087; XmAb 20717; XmAb 22841; XmAb 23104; XmAb 5483; XmAb bispecific x4; XmAb®5485

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xencor
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors; CD20 antigen inhibitors; CD20 antigen modulators; CD3 antigen inhibitors; CD3 antigen modulators; CD38 antigen inhibitors; CD38 antigen modulators; CD40 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; Fc gamma receptor IIB modulators; Glutamate carboxypeptidase II inhibitors; Interleukin 3 receptor alpha subunit modulators; Interleukin-3-receptor-alpha-subunit-antagonists; PDCD 1 protein inhibitors; Signal transduction pathway inhibitors; Somatostatin receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; B cell lymphoma; Cancer; Haematological malignancies; Multiple myeloma; Neuroendocrine tumours
  • Research Immunological disorders

Most Recent Events

  • 08 Nov 2017 Antibody therapeutics are still in preclinical development for Cancer and Haematological malignancies in USA (Xencor pipeline, November 2017)
  • 07 Nov 2017 Xencor receives IND approval for XmAb 18087 in Neuroendocrine tumours and Gastrointestinal stromal tumours
  • 07 Nov 2017 Xencor announces intention to submit IND applications for XmAB 20717, XmAB 22841 and XmAB 23104 in multiple oncology indications in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top